The personalised cancer therapy company has completed a $40m round that increased its funding to $76m altogether.

University of Tokyo Edge Capital joined a second close that expanded the cell therapy developer's series B round by an extra $11m.

Cryptocurrency exchange platform Binance has invested in a first round for Oasis Labs, based on research by Dawn Song at UC Berkeley.

Andera Partners has led a $55m funding round for Dynacure, co-founded by Satt Conectus to commercialise research from the Institute of Genetic and Molecular and Cellular Biology.

IP Group and Penn Medicine have both returned to back a series A round for Carisma Therapeutics, the Pennsylvania spinout formerly known as Carma.

The spinout has bagged support from Inserm Transfert Initiative and two Bpifrance-managed funds for its clinical-stage therapy for hepatitis B.

6 Dimensions Capital led a round for the miniprotein drug developer, founded by Harvard researcher Gregory Verdine.

Celsius Therapeutics, which has launched with series A capital, has become the latest Third Rock-launched company to be backed by GV.